| |

New ‘Drug Factory’ Implant Eliminates Mesothelioma in Mice

New ‘Drug Factory’ Implant Eliminates Mesothelioma in Mice

A new ‘drug factory’ implant has eliminated advanced-stage mesothelioma tumors in mice. The treatment is effective in just a few days. It works by combining a “drug factory” implant with a checkpoint inhibitor drug.

The news comes from researchers at Rice University and Baylor College of Medicine. The treatment worked in 100% of the animals treated. And it shows amazing hope for the future of mesothelioma.

How the Treatment Works

The treatment uses tiny drug-producing beads no larger than the tip of a needle. The beads go to work next to the mesothelioma tumor. Here, they work to produce continuous, high doses of interleukin-2 (IL-2). IL-2 is a natural compound that triggers white blood cells to fight cancer.

The study was published in Clinical Cancer Research. It is the latest in a series of successes for this ‘drug-factory’ invention. This technology was invented in the lab of bioengineer Omid Veiseh. They recently received FDA approval to begin clinical trials.

These tiny cytokine factories are made up of alginate beads. Each bead is loaded with thousands of genetically engineered cells that produce IL-2. This is one of two cytokines that the FDA has approved for cancer treatment.

The ‘drug factories’ are extremely small. They can be placed with minimally invasive surgery. This is welcome news to mesothelioma patients. The treatment is designed to deliver high doses of IL-2 directly to cancer tumors. In the mesothelioma study, the beads were implanted directly onto the pleura.

This treatment approach had great success first in ovarian cancer. This is the first time it has been applied in mesothelioma. Mesothelioma is the asbestos-caused cancer.

Immunotherapy treatment has been successful in treating mesothelioma with drugs called checkpoint inhibitors. Checkpoint inhibitors do not kill cancer directly. They work by teaching the immune system to recognize and destroy cancer cells.

They tested the ‘drug factory’ by themselves and in combination with checkpoint inhibitors. They found the ‘drug factory’ implant alone eliminated tumors in 50% of the treated animals. Tumors were eliminated in 100% of the animals with both the implant and checkpoint inhibitors.

Sources:

Nash, Amanda M., Samira Aghlara-Fotovat, Bertha Castillio, Andrea Hernandez, Aarthi Pugazenthi, Hyun-Sung Lee, Hee-Jin Jang et al. “Activation of adaptive and innate immune cells via localized Interleukin-2 cytokine factories eradicates mesothelioma tumors.” Clinical Cancer Research: an Official Journal of the American Association for Cancer Research (2022): CCR-22. https://doi.org/10.1158/1078-0432.CCR-22-1493

‘Drug factory’ implants eliminate mesothelioma tumors in mice. Rice News | News and Media Relations | Rice University. Accessed September 12, 2022. https://news.rice.edu/news/2022/drug-factory-implants-eliminate-mesothelioma-tumors-mice

 

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…